141
Participants
Start Date
January 8, 2008
Primary Completion Date
February 4, 2010
Study Completion Date
February 1, 2012
Entinostat
Entinostat tablets on Days 1 and 15 of a 28-day cycle.
Placebo
Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
Erlotinib
Erlotinib 150 mg tablets once daily.
HOPE (Hematology Oncology Physicians & Extenders), Tucson
Rocky Mountain Cancer Center, Denver
Advanced Medical Specialties, Miami
Ocala Oncology Center, Ocala
Cancer Centers of Florida, Ocoee
Hematology Oncology Associates of Illinois, Chicago
Central Indiana Cancer Centers, Indianapolis
Kansas City Cancer Centers, Overland Park
Alliance Hematology Oncology, Westminster
St Joseph Oncology, Saint Joseph
The Center for Cancer Care & Research, St Louis
Mahonig Valley Hematology Oncology Associates, Boardman
Dayton Oncology & Hematology, Kettering
Oncology Associates of Oregon, Eugene
Texas Oncology, Amarillo
Texas Oncology, Austin
Texas Oncology, Bedford
Texas Oncology, Sammons Cancer Center, Dallas
Texas Oncology, Dallas
Texas Oncology, Fort Worth
Texas Oncology, Garland
Texas Oncology, Longview
Texas Oncology, Midland
Texas Oncology, Odessa
Texas Oncology, Tyler
Fairfax Northern Virginia Hematology-Oncology, Fairfax
Virginia Oncology Associates, Norfolk
Highline Medical Oncology, Burien
Cancer Care Northwest, Spokane
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
Lead Sponsor
Syndax Pharmaceuticals
INDUSTRY